Recently, Debashis Dutta et al. demonstrated that, by specifically targeting the TLR2/NF-κB pathway, it is possible to reduce the a-synuclein spreading in vitro and in vivo, finally contributing to the treatment of neurodegenerative diseases such as Parkinson’s disease (PD) [117]. This evidence concerns the gene NFKB1 and neurodegenerative disease.